Skip to main content
Top
Published in: Supportive Care in Cancer 4/2011

01-04-2011 | Original Article

Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unit

Authors: Jae-Uk Song, Gee Young Suh, Man Pyo Chung, Hojoong Kim, O Jung Kwon, Chul Won Jung, Won Ki Kang, Keunchil Park, Kyeongman Jeon

Published in: Supportive Care in Cancer | Issue 4/2011

Login to get access

Abstract

Objective

The decision to start chemotherapy in critically ill cancer patients is extremely complex in the intensive care unit (ICU). Therefore, this study evaluated the outcomes and prognostic factors in critically ill cancer patients receiving chemotherapy in the ICU.

Methods

A retrospective analysis was performed using 62 cancer patients who received chemotherapy in the ICU between October 2002 and December 2008. The dataset included 49 hematologic malignancies (79%) and 13 solid tumors (21%).

Results

Twenty (32%) patients were admitted to the ICU with septic shock, 15 (24%) with respiratory failure, and 14 (23%) with renal failure. The median SOFA and SAPS II scores at the time of chemotherapy were 10 (interquartile range, 6–14) and 53 (interquartile range, 41–68), respectively. Twenty-three (37%) patients had concomitant infections when chemotherapy was initiated. Thirty-eight (61%) patients received mechanical ventilation, and 19 (31%) patients underwent renal replacement therapy at the moment of chemotherapy. Overall, 25 (40%) patients died in the ICU; death occurred due to septic shock (13, 52%), cancer progression (9, 36%), or bleeding (2, 8%). ICU mortality after chemotherapy was correlated with respiratory failure requiring mechanical ventilation (OR, 6.26; 95% CI, 1.12–34.95) and a SOFA score of ≥10 (OR, 9.66; 95% CI, 1.43–65.47) upon initiating chemotherapy.

Conclusions

Chemotherapy in the ICU for critically ill cancer patients can be considered even when infection or organ failure is present. However, the severity of organ failure, including respiratory failure requiring mechanical ventilation, was associated with an increased mortality after chemotherapy during an ICU stay.
Literature
1.
go back to reference Schapira DV, Studnicki J, Bradham DD, Wolff P, Jarrett A (1993) Intensive care, survival, and expense of treating critically ill cancer patients. JAMA 269:783–786PubMedCrossRef Schapira DV, Studnicki J, Bradham DD, Wolff P, Jarrett A (1993) Intensive care, survival, and expense of treating critically ill cancer patients. JAMA 269:783–786PubMedCrossRef
2.
3.
go back to reference Azoulay E, Alberti C, Bornstain C, Leleu G, Moreau D, Recher C, Chevret S, Le Gall JR, Brochard L, Schlemmer B (2001) Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support. Crit Care Med 29:519–525PubMedCrossRef Azoulay E, Alberti C, Bornstain C, Leleu G, Moreau D, Recher C, Chevret S, Le Gall JR, Brochard L, Schlemmer B (2001) Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support. Crit Care Med 29:519–525PubMedCrossRef
4.
go back to reference Larche J, Azoulay E, Fieux F, Mesnard L, Moreau D, Thiery G, Darmon M, Le Gall JR, Schlemmer B (2003) Improved survival of critically ill cancer patients with septic shock. Intensive Care Med 29:1688–1695PubMedCrossRef Larche J, Azoulay E, Fieux F, Mesnard L, Moreau D, Thiery G, Darmon M, Le Gall JR, Schlemmer B (2003) Improved survival of critically ill cancer patients with septic shock. Intensive Care Med 29:1688–1695PubMedCrossRef
5.
go back to reference Moran JL, Solomon PJ, Williams PJ (2005) Assessment of outcome over a 10-year period of patients admitted to a multidisciplinary adult intensive care unit with haematological and solid tumours. Anaesth Intensive Care 33:26–35PubMed Moran JL, Solomon PJ, Williams PJ (2005) Assessment of outcome over a 10-year period of patients admitted to a multidisciplinary adult intensive care unit with haematological and solid tumours. Anaesth Intensive Care 33:26–35PubMed
6.
go back to reference Azoulay E, Afessa B (2006) The intensive care support of patients with malignancy: do everything that can be done. Intensive Care Med 32:3–5PubMedCrossRef Azoulay E, Afessa B (2006) The intensive care support of patients with malignancy: do everything that can be done. Intensive Care Med 32:3–5PubMedCrossRef
7.
go back to reference Darmon M, Thiery G, Ciroldi M, de Miranda S, Galicier L, Raffoux E, Le Gall JR, Schlemmer B, Azoulay E (2005) Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med 33:2488–2493PubMedCrossRef Darmon M, Thiery G, Ciroldi M, de Miranda S, Galicier L, Raffoux E, Le Gall JR, Schlemmer B, Azoulay E (2005) Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med 33:2488–2493PubMedCrossRef
8.
go back to reference Benoit DD, Depuydt PO, Vandewoude KH, Offner FC, Boterberg T, De Cock CA, Noens LA, Janssens AM, Decruyenaere JM (2006) Outcome in severely ill patients with hematological malignancies who received intravenous chemotherapy in the intensive care unit. Intensive Care Med 32:93–99PubMedCrossRef Benoit DD, Depuydt PO, Vandewoude KH, Offner FC, Boterberg T, De Cock CA, Noens LA, Janssens AM, Decruyenaere JM (2006) Outcome in severely ill patients with hematological malignancies who received intravenous chemotherapy in the intensive care unit. Intensive Care Med 32:93–99PubMedCrossRef
9.
go back to reference Park HY, Suh GY, Jeon K, Koh WJ, Chung MP, Kim H, Kwon OJ, Kim K, Jang JH, Jung CW, Kang E, Kim MJ (2008) Outcome and prognostic factors of patients with acute leukemia admitted to the intensive care unit for septic shock. Leuk Lymphoma 49:1929–1934PubMedCrossRef Park HY, Suh GY, Jeon K, Koh WJ, Chung MP, Kim H, Kwon OJ, Kim K, Jang JH, Jung CW, Kang E, Kim MJ (2008) Outcome and prognostic factors of patients with acute leukemia admitted to the intensive care unit for septic shock. Leuk Lymphoma 49:1929–1934PubMedCrossRef
10.
go back to reference Brenner H (2002) Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 360:1131–1135PubMedCrossRef Brenner H (2002) Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 360:1131–1135PubMedCrossRef
11.
go back to reference Johnson MH, Gordon PW, Fitzgerald FT (1986) Stratification of prognosis in granulocytopenic patients with hematologic malignancies using the APACHE-II severity of illness score. Crit Care Med 14:693–697PubMedCrossRef Johnson MH, Gordon PW, Fitzgerald FT (1986) Stratification of prognosis in granulocytopenic patients with hematologic malignancies using the APACHE-II severity of illness score. Crit Care Med 14:693–697PubMedCrossRef
12.
go back to reference Lloyd-Thomas AR, Dhaliwal HS, Lister TA, Hinds CJ (1986) Intensive therapy for life-threatening medical complications of haematological malignancy. Intensive Care Med 12:317–324PubMedCrossRef Lloyd-Thomas AR, Dhaliwal HS, Lister TA, Hinds CJ (1986) Intensive therapy for life-threatening medical complications of haematological malignancy. Intensive Care Med 12:317–324PubMedCrossRef
13.
go back to reference Lloyd-Thomas AR, Wright I, Lister TA, Hinds CJ (1988) Prognosis of patients receiving intensive care for life threatening medical complications of haematological malignancy. Br Med J (Clin Res Ed) 296:1025–1029CrossRef Lloyd-Thomas AR, Wright I, Lister TA, Hinds CJ (1988) Prognosis of patients receiving intensive care for life threatening medical complications of haematological malignancy. Br Med J (Clin Res Ed) 296:1025–1029CrossRef
14.
go back to reference Groeger JS, Lemeshow S, Price K, Nierman DM, White P Jr, Klar J, Granovsky S, Horak D, Kish SK (1998) Multicenter outcome study of cancer patients admitted to the intensive care unit: a probability of mortality model. J Clin Oncol 16:761–770PubMed Groeger JS, Lemeshow S, Price K, Nierman DM, White P Jr, Klar J, Granovsky S, Horak D, Kish SK (1998) Multicenter outcome study of cancer patients admitted to the intensive care unit: a probability of mortality model. J Clin Oncol 16:761–770PubMed
15.
go back to reference Darmon M, Azoulay E, Alberti C, Fieux F, Moreau D, Le Gall JR, Schlemmer B (2002) Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients. Intensive Care Med 28:1775–1780PubMedCrossRef Darmon M, Azoulay E, Alberti C, Fieux F, Moreau D, Le Gall JR, Schlemmer B (2002) Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients. Intensive Care Med 28:1775–1780PubMedCrossRef
16.
go back to reference Vandijck DM, Benoit DD, Depuydt PO, Offner FC, Blot SI, Van Tilborgh AK, Nollet J, Steel E, Noens LA, Decruyenaere JM (2008) Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies. Intensive Care Med 34:847–855PubMedCrossRef Vandijck DM, Benoit DD, Depuydt PO, Offner FC, Blot SI, Van Tilborgh AK, Nollet J, Steel E, Noens LA, Decruyenaere JM (2008) Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies. Intensive Care Med 34:847–855PubMedCrossRef
Metadata
Title
Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unit
Authors
Jae-Uk Song
Gee Young Suh
Man Pyo Chung
Hojoong Kim
O Jung Kwon
Chul Won Jung
Won Ki Kang
Keunchil Park
Kyeongman Jeon
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 4/2011
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-0841-x

Other articles of this Issue 4/2011

Supportive Care in Cancer 4/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine